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INTRODUCTION 
The immune system is a complex network of organs, cells and molecules that has 
evolved to protect the body from invading pathogenic microorganisms and cancer. At 
the same time the immune system can be detrimental and cause disease as seen in 
autoimmune diseases. The immune system is traditionally divided into two parts: the 
innate and the adaptive immune system. The innate immune system provides the first 
line of defense against infection and most components including phagocytic cells, 
complement and natural killer cells, are present before the onset of infection. The 
innate immune response responds rapidly, but in contrast to the adaptive immune 
system it does not have an immunological memory. The adaptive immune response is 
dependent on antigen specific receptors on the surface of B and T lymphocytes. This 
response takes days to develop as there are few specific lymphocytes for the invading 
pathogen that have to undergo clonal expansion. Following elimination of the 
pathogen, a subset of the cells remains as memory cells that respond faster and 
stronger to a subsequent encounter with the pathogen. 
 
Major histocompatibility complex (MHC) molecules are expressed on most cells in 
the body. In humans these molecules are called human leukocyte antigen (HLA). The 
function of MHC molecules is to display peptide antigens to T cells. MHC class I 
molecules are expressed on nearly all nucleated cells, while MHC class II molecules 
are constitutively expressed on professional antigen presenting cells (APC). The 
APCs include dendritic cells, B cells, macrophages and thymic epithelial cells. 
Peptides from the cells’ own proteins or from bacteria, virus or ingested antigen are 
presented on the MHC molecules. These peptide-MHC complexes are scanned by 
circulating T cells. When a naïve T cell recognizes a peptide-MHC complex, a 
signaling cascade is initiated and the T cell is activated. Activated T cells can mediate 
their effects through cytotoxic mechanisms or through cytokine production. In 
humans, three isotypes of class II molecules are expressed: HLA-DR, HLA-DQ and 
HLA-DP. 
 
Autoimmune diseases are characterized by an immune mediated damage of cells or 
tissues. The causes of autoimmune diseases are unknown. However both genetic and 
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environmental factors are involved. For most diseases, like type 1 diabetes, 
rheumatoid arthritis and multiple sclerosis the environmental factor is unknown. For 
celiac disease, which has several autoimmune features, the antigen is known to be 
gluten. Gluten is an exogenous antigen and celiac disease may therefore also be 
categorized as food hypersensitivity or allergic disease. The MHC is the major genetic 
susceptibility factor for autoimmunity. It is located on the short arm of chromosome 6 
(6p21.3). The extended HLA complex contains 252 genes and spans 7.6 Mb (Horton 
et al., 2004). A recent genome wide association study on several autoimmune diseases 
revealed that HLA is by far the most important susceptibility factor for many of these 
diseases (The Wellcome Trust Case Control Consortium, 2007). Yet, the molecular 
mechanism for the HLA association for most diseases is unknown. Celiac disease has 
become a valuable model for the study of HLA associated diseases. In such a model 
the primary HLA association and the antigen should be known and the antigen 
specific T cell should be possible to isolate and grow. In celiac disease all these 
criteria are fulfilled. There is a strong association with HLA-DQ2 and -DQ8, gluten is 
found to be the antigen and gluten specific T cells from the intestine of celiac disease 
patients can be cultured from biopsies. 
 
The goal of my work has been to further investigate how peptides bind to HLA-DQ2 
and to start developing peptide blockers for the treatment of celiac disease. 
 
MHC class II molecules 
Structure of MHC class II molecules and peptide binding 
The MHC class II molecules are membrane-bound glycoproteins consisting of two 
subunits, the 29 kDa -chain and the 32 kDa -chain. Each chain consists of two 
extracellular domains (1 and 2, 1 and 2), a transmembrane region and a short 
cytoplasmic domain. The membrane distal domains (1 and 1) form the peptide 
binding groove which consists of eight strands of anti-parallel -sheets with two 
antiparallel -helical regions overlaying them. The deep cleft formed between the -
helices accommodates the peptide. In contrast to MHC class I molecules, the MHC 
class II molecules have a peptide binding site with open ends allowing peptides with 
variable length to bind (Madden, 1995). Studies have shown that peptides eluted from 
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MHC class II molecules are normally between 10 and 34 amino acids long (Rudensky 
et al., 1991; Hunt et al., 1992; Chicz et al., 1993). Their function is to bind and present 
fragments of degraded proteins to CD4+ T cells (Germain, 1994). The determination 
of the three-dimensional structure by x-ray crystallography has revealed that peptides 
are bound in an extended conformation within a groove formed by the - and -chain 
of the MHC class II molecule, adopting a polyproline type II helical conformation 
(Stern et al., 1994; Jardetzky et al., 1996). A seven stranded -sheet represents the 
floor of the binding groove and the sides are formed by two long -helices. Two 
mechanisms are involved in the stable binding of peptides to the MHC class II 
molecule. Hydrogen bonding between highly conserved residues of the MHC class II 
molecule and carbonyl oxygen and amide nitrogen of the peptide backbone is one 
mechanism (Stern et al., 1994; Jardetzky et al., 1996). The other mechanism includes 
the extensive polymorphic residues situated around the peptide binding site which 
results in the formation of pockets that can bury amino acid side chains of the bound 
peptide at the P1, P4, P6, P7 and P9 positions (Stern et al., 1994). These 
polymorphisms in MHC class II molecules are responsible for the allele specific 
peptide binding motifs for each molecule. The side chains of residues P2, P5 and P8 
are found to point outward in the direction of the T cell receptor (TCR) (Stern et al., 
1994) (Figure 1). 
 
 
Figure 1. Schematic representation of peptide, MHC and TCR. 
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Antigen processing 
The APCs display a complex of peptide and MHC class II molecule for recognition 
by CD4+ T cells (Babbitt et al., 1985). These peptides usually derive from exogenous 
antigens which can be internalized in APC through receptor-mediated endocytosis, 
phagocytosis or macropinocytosis (Watts, 1997). The antigens are unfolded and 
degraded into peptides within the endocytic pathway by low pH, reducing conditions 
and proteolytic activity in the endosomes (Jensen, 1995). 
 
The MHC class II  heterodimer is assembled in the endoplasmic reticulum (ER) 
where it associates with the chaperone molecule invariant chain (Ii), which ensures 
correct folding of the MHC class II molecule (Cresswell, 1996). A trimer of Ii 
associates with three MHC class II molecules to form a nonameric complex (Ii)3 
(Roche et al., 1991). This complex is transported from the ER, through the Golgi 
apparatus to late endosomal vesicles called MHC class II compartments (MIIC) 
(Peters et al., 1991). This transport is directed by targeting signals in the cytoplasmic 
domain of Ii (Bakke and Dobberstein, 1990). In these vesicles, Ii is proteolytically 
degraded leaving a short fragment called CLIP (class II-associated Ii peptide) bound 
to the binding groove of the MHC class II molecule. CLIP contributes to MHC 
stability and prevents loading of endogenous peptides in the ER (Roche and 
Cresswell, 1990; Busch et al., 1996). The release of CLIP is catalyzed by HLA-DM 
and is required for binding of antigenic peptides (Denzin and Cresswell, 1995; 
Sherman et al., 1995). The MHC class II-peptide complex is subsequently transported 
to the cell surface for inspection by CD4+ T cells. HLA-DM is a non-classical MHC 
class II molecule, which is unable to bind peptides due to a closed peptide binding 
groove. In addition to catalyzing the release of CLIP, HLA-DM stabilizes the empty 
form of the MHC class II molecule (Kropshofer et al., 1997) and edits the repertoire 
of bound peptides. A second non-classical MHC class II molecule, called HLA-DO is 
associated with HLA-DM (Liljedahl et al., 1996) and acts as a negative regulator of 
HLA-DM (Denzin et al., 1997; van Ham et al., 1997; Liljedahl et al., 1998). 
 
Peptide binding to HLA-DQ2 
The peptide binding motif of HLA-DQ2 was first characterized by sequencing of 
peptides eluted from affinity purified molecules (van de Wal et al., 1996; Vartdal et 
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al., 1996) and by binding experiments with substituted and truncated variants of high 
affinity binding peptides (Johansen et al., 1996; van de Wal et al., 1996; Vartdal et al., 
1996). The results demonstrated a preference for negatively charged anchor residues 
in the P4, P6 and P7 pockets and bulky hydrophobic residues in P1 and P9. 
 
The first x-ray crystal structure of a MHC class II molecule was reported in 1993 
(Brown et al., 1993). Since then more than 20 crystal structures have been solved. 
Kim et al solved the x-ray crystal structure of HLA-DQ2 complexed with a gluten 
peptide, QLQPFPQPELPY (DQ2--I-gliadin peptide) with a resolution of 2.2Å (Kim 
et al., 2004). This study provided definite information about the interaction between 
peptide and HLA-DQ2. In Figure 2, the binding site of HLA-DQ2 with its pockets is 
shown with and without the DQ2--I-gliadin peptide. Despite the presence of four Pro 
residues in the peptide, the critical hydrogen bonds between HLA-DQ2 and the 
peptide are retained. As Pro residues are not able to participate in amide-mediated 
hydrogen bonds, the positioning is such that they do not interfere with the hydrogen 
bonds. The amide mediated hydrogen bonds are seen in positions 2, 4, 6 and 9. In 
crystal structures of other MHC class II molecules there is an amide mediated 
hydrogen bond also in position 1 (Stern et al., 1994; Ghosh et al., 1995; Fremont et 
al., 1996; Dessen et al., 1997; Fremont et al., 1998; Scott et al., 1998; Smith et al., 
1998; Latek et al., 2000; Lee et al., 2001; He et al., 2002; Liu et al., 2002b; Zhu et al., 
2003; Siebold et al., 2004; Henderson et al., 2007). This bond is not seen in HLA-
DQ2 since there is a Pro residue in this position. The crystal structure also revealed 
that the Glu residue at P6 is an important anchor residue due to its participation in an 
extensive hydrogen bonding network involving Lys-71.  
 
 
 
 
 
 
 
 
 
 A 
 
B
 
C 
 
 
Figure 2. Pockets in the peptide binding groove of HLA-DQ2. A. The surface of the 
HLA-DQ2 peptide binding groove with the pockets labeled after the amino acid side 
chain accommodated. B. DQ2--I-gliadin peptide bound in the binding groove. The 
side chains of P2, P5 and P8 extend in the direction of the TCR. Carbon atoms are 
yellow, nitrogen atoms are blue and oxygen atoms are red. C. Side view of the peptide 
binding groove. The surface is shown as a grey mesh. Figures were generated using 
PyMol (DeLano Scientific LLC). 
 
 
T cell recognition 
Most T lymphocytes express an  TCR. These T cells can be separated into two 
subsets on the basis of the cell-surface markers CD4 and CD8. The CD8+ T cells 
usually recognize peptides presented by MHC class I molecules, whereas CD4+ T 
cells recognize peptides presented by MHC class II molecules. 
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The TCR is a heterodimer consisting of either - and -chains or - and -chains 
linked by a disulfide bond. Each chain is composed of variable and constant Ig-like 
domains, a transmembrane domain and a short cytoplasmic tail. Only a minority of 
the T cells has a TCR made up of - and -chains and the function of these  T cells 
is not yet completely understood. The  TCR binds the peptide-MHC complex 
through complementarity determining regions (CDR) present in their variable 
domains. 
 
Activation of CD4+ T cells take place via interaction of the TCR with a peptide bound 
to a MHC class II molecule on an APC. As the peptide is bound in a polyproline type 
II helical conformation, only a few of the peptide side chains are available for direct 
interaction with the TCR. The other side chains are accommodated in pockets in the 
MHC class II molecule. Recognition of a peptide-MHC complex is the first of two 
signals required for full T cell activation. The second signal is provided by a variety 
of co-stimulatory molecules expressed on the surface of T cells such as CD28, CTLA-
4 or CD40L which interact with their counterparts on the APC. This second signal 
may strengthen or weaken the TCR signal. When a T cell is fully activated it becomes 
less dependent on the co-stimulatory signals on later restimulation. 
 
Based on the outcome of the interaction between TCR and peptide-MHC, peptides 
can be classified as agonists, weak agonist, partial agonist, antagonist or null 
compounds. An altered peptide ligand (APL) is a peptide where single or multiple 
amino acid replacements cause a different activation of the T cells as a result of the 
modified interaction with the TCR. Agonists induce full T cell stimulation, while an 
antagonist do not induce any function and block this stimulation by modifying 
signaling pathways downstream of the TCR. Weak agonists are able to induce full T 
cell stimulation at high concentrations while partial agonists induce some but not all T 
cell functions (e.g. cytokine secretion without proliferation) (Sloan-Lancaster and 
Allen, 1996; Bielekova and Martin, 2001). 
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Celiac disease 
Clinical aspects 
Celiac disease is a chronic inflammatory disorder of the small intestine induced by 
dietary proteins in wheat, rye and barley. It was first described by Samuel Gee in 1888 
(Gee, 1888). The chronic inflammation of the small intestine results in the celiac 
lesion, characterized by villous atrophy, crypt hyperplasia and infiltration of lymphoid 
cells in the epithelium and lamina propria (Trier, 1991). These pathological findings 
are reversed on withdrawal of gluten from the diet. The symptoms in early childhood 
typically include chronic diarrhea, abdominal distension, failure to thrive and 
malabsorption (Mäki and Collin, 1997). When the disease presents later in life, the 
symptoms tend to be more vague and they include weight loss, diarrhea, constipation 
and extraintestinal symptoms like anemia, fatigue, neurological symptoms and 
behavioral disturbances as depression and irritability (Fasano and Catassi, 2001). The 
fact that many patients have only mild or no symptoms leads to the high frequency of 
undiagnosed patients. Untreated celiac disease is associated with complications such 
as infertility, osteoporosis and intestinal malignancies (Mäki and Collin, 1997) in 
addition to increased mortality (Corrao et al., 2001; Fasano and Catassi, 2001).  
 
Untreated celiac disease patients have increased levels of serum antibodies for gluten 
and transglutaminase 2 (TG2) and testing of these are utilized to predict celiac 
disease. However, a positive serologic test has to be confirmed by the findings of 
typical histological alterations of the small intestinal mucosa by a biopsy for a definite 
diagnosis of celiac disease. Development of sensitive serological tests has made 
screening studies possible. These studies have demonstrated that the prevalence of 
celiac disease may be as high as 1:100 in Caucasians (Mäki et al., 2003; Dube et al., 
2005). 
 
Genetic factors 
Celiac disease develops as a result of interplay between genetic and environmental 
factors. The genetic factor was evident from clinical observations of multiple cases of 
celiac disease within families, with about 10% of first-degree relatives being affected 
(Petronzelli et al., 1997) and a high rate of concordance (75%) for celiac disease 
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among monozygotic twins (Greco et al., 2002; Nistico et al., 2006). HLA-DQ2 and 
-DQ8 have been identified as the key genetic risk factors in celiac disease (Sollid and 
Thorsby, 1993). It has been estimated that the HLA genes account for around 50% of 
the genetic heritability of celiac disease (Sollid and Lie, 2005). More than 90% of 
celiac disease patients express the HLA-DQ2.5 heterodimer (DQA1*05/DQB1*02) 
compared to a prevalence of 30% among the general population (Sollid et al., 1989; 
Sollid and Thorsby, 1993). Most of the remaining individuals express HLA-DQ8 
(DQA1*0301/DQB1*0302). The celiac disease associated HLA-DQ2.5 can be 
encoded in cis (on one chromosome) by DQ alleles of the DR3-DQ2 haplotype, or in 
trans (across both chromosomes) by the DR5-DQ2 and DR7-DQ2 haplotypes. Among 
the few celiac disease patients who are neither HLA-DQ2.5 nor -DQ8 there are some 
patients carrying HLA-DQ2.2 (DQA1*0201/DQB1*0202) from the DR7-DQ2 
haplotype (Karell et al., 2003). In the membrane distal domains HLA-DQ2.2 and 
-DQ2.5 have identical sequence in their  chains while the  chains differ by ten 
amino acids. 
 
As celiac disease only occurs in a small portion of the population carrying HLA-DQ2 
and -DQ8, additional factors clearly contribute. This means that HLA-DQ2 and -DQ8 
are necessary but not sufficient for development of celiac disease and has led to a hunt 
for other candidate genes. A variety of candidate regions have been identified (Djilali-
Saiah et al., 1998; Greco et al., 2001; Liu et al., 2002a; Woolley et al., 2002; van 
Belzen et al., 2003; Monsuur et al., 2005), but until recently no susceptibility genes 
other than HLA-DQ have been identified and convincingly replicated. Recently a 
genome-wide association study by van Heel et al (van Heel et al., 2007) identified 
genetic elements predisposing to celiac disease in a region on chromosome 4q27 that 
contains the IL2, IL21, TENR and KIAA1109 genes. In addition Alizadeh and 
coworkers found that homozygosity for a variant of the FcgRIIa gene predisposes to 
celiac disease (Alizadeh et al., 2007). Both of these findings need to be replicated. 
Based on the current knowledge it seems reasonable to assume that a number of 
different genes predispose to celiac disease development, and that the constellation of 
predisposing genes may vary between the individual celiac disease patients. 
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Gluten – the environmental factor 
Gluten is obviously the critical environmental factor as the disease goes into 
remission when gluten is eliminated from the diet. The triggering factor of celiac 
disease was found to be gluten more than 50 years ago by Dicke and coworkers 
(Dicke et al., 1953). Gluten is the storage protein of wheat and is responsible for the 
unique baking properties of wheat. It is traditionally divided into two groups based on 
solubility in aqueous alcohol, gliadins (soluble fraction) and glutenins (alcohol 
insoluble fraction). Gliadins are further classified into three groups, -, - and -
gliadins, based on their amino acid sequences (Wieser et al., 1987) and glutenins into 
high molecular weight (HMW) and low molecular weight (LMW) glutenin subunits. 
 
The closely related proteins in rye and barley are secalins and hordeins, respectively. 
Collectively, these storage proteins in cereal grains are often named prolamins and 
they contain a high percentage of Pro and Gln residues. Based on the primary amino 
acid sequence there are many similarities between the gliadins and glutenins with 
many repetitive sequences. It has been shown that both gliadins and glutenins are 
toxic for the celiac disease patients (Ciclitira et al., 1984; Lundin et al., 1993; Lundin 
et al., 1994; Molberg et al., 1997; van de Wal et al., 1999; Vader et al., 2002b; 
Molberg et al., 2003; Spaenij-Dekking et al., 2005b; Dewar et al., 2006). 
 
Avenin is the prolamin fraction of oats. Whether oats could be included in a gluten 
free diet or not has been controversial and several clinical studies have indicated that 
oats in the diet is safe for most celiac disease patients (reviewed in Haboubi et al., 
2006). However there are studies showing that some celiac disease patients have 
avenin-reactive mucosal T cells (Arentz-Hansen et al., 2004). 
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Pathogenesis – involvement of adaptive and innate immunity  
Celiac disease is the result of an abnormal CD4+ T cell initiated immune response to 
wheat gluten (Figure 3). Gluten reactive CD4+ T cells can be isolated and cultured 
from small intestinal biopsies of celiac disease patients, but not from healthy controls 
(Lundin et al., 1993; Lundin et al., 1994; Molberg et al., 1997). Upon recognition of 
gluten peptides, these T cells are activated and a cytokine response strongly 
dominated by interferon- (IFN-) is induced (Nilsen et al., 1998). These T cells are 
exclusively restricted by HLA-DQ2 and -DQ8. It was demonstrated by Ráki et al that 
a unique subset of dendritic cells is responsible for the activation of gluten reactive T 
cells in the celiac lesion (Ráki et al., 2006).  
 
A growing number of gluten derived epitopes recognized by T cells from the 
intestinal mucosa of celiac disease patients have been described (Sjöström et al., 
1998; van de Wal et al., 1998b; Arentz-Hansen et al., 2000; Arentz-Hansen et al., 
2002; Vader et al., 2002b). Most of these epitopes are dependent on a conversion of 
Gln to Glu residues for T cell recognition. This process, which is called deamidation, 
is mediated by the enzyme TG2. The introduction of a negatively charged residue 
increases the binding affinity for DQ2 (Molberg et al., 1998; van de Wal et al., 
1998a). Notably, the T cell recognition seems to be more sensitive to the Gln to Glu 
exchange than what can be explained by the increased binding alone (Arentz-Hansen 
et al., 2000). TG2 shows a specificity for selected Gln residues in the gluten peptide 
(Fleckenstein et al., 2002; Vader et al., 2002a). It was demonstrated by Arentz-Hansen 
et al that the gliadin epitopes cluster in Pro-rich regions. The high Pro content makes 
them exceptionally resistant to gastric, pancreatic and intestinal proteases and 
peptidases (Hausch et al., 2002; Shan et al., 2002; Shan et al., 2005). 
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Figure 3. The celiac lesion. A. Gluten is digested into amino acids and peptides by 
luminal and brush-border enzymes. Some Pro-rich fragments of gluten are resistant 
to proteolysis and these peptides can be transported across the epithelium into the 
lamina propria where they are deamidated by TG2. CD4+ T cells in the lamina 
propria recognize deamidated gluten peptides presented by HLA-DQ2 or -DQ8 
molecules on the surface of APC. There is infiltration of intraepithelial lymphocytes in 
the epithelium. These CD8+ T cells express NK cell receptors like NKG2D and are 
able to kill enterocytes that express stress induced molecules like MICA. Gluten 
stimulates the expression of IL-15 which can induce upregulation of NKG2D and 
MICA. A yellow star indicates possible treatment strategies. B. Model of mechanism 
for production of antibodies to TG2. Complexes of gluten peptide and TG2 are formed 
during the deamidation reaction. These complexes can be bound by immunoglobulin 
(Ig) on the surface of TG2-specific B cells and endocytosed. The deamidated gluten 
peptide can bind to HLA-DQ2 or -DQ8 and be presented to CD4+ T cells. The T cell 
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recognition will provide help signals to the B cells necessary for secretion of 
antibodies. 
 
More recent studies suggest that the innate immune system is important in celiac 
disease pathogenesis. A hallmark of celiac disease is an increase in the number of 
intraepithelial lymphocytes (IEL), most of which are CD8+ cytotoxic T cells. These 
IELs have been shown to mediate the destruction of the enterocytes in celiac disease 
(Hüe et al., 2004; Meresse et al., 2006). Interleukin (IL)-15 is also implicated in this 
process. This cytokine can be induced by gliadin (Maiuri et al., 2000; Maiuri et al., 
2003; Mention et al., 2003). Gliadin and the -gliadin derived peptide, p31-49 are 
shown to induce expression of MICA on epithelial cells, probably via IL-15 (Hüe et 
al., 2004). Up-regulation of NKG2D on the IELs is also mediated via IL-15 (Roberts 
et al., 2001; Meresse et al., 2004). The interaction between NKG2D and MICA leads 
to enterocyte killing, but no proliferation or cytokine secretion (Hüe et al., 2004). 
Recently Meresse et al demonstrated that CD94-NKG2C recognizing HLA-E on 
epithelial cells is expressed on IELs in celiac disease patients (Meresse et al., 2006). 
The stress-induced molecule HLA-E is induced by IFN- (Perera et al., 2007), which 
in turn is produced by gluten reactive CD4+ T cells in lamina propria and by the IELs. 
This interaction between CD94-NKG2C and HLA-E can induce cytokine secretion 
and proliferation, as well as cytolysis, and helps to explain the IFN- production and 
the expansion of IELs. 
 
Treatment of celiac disease 
The only available treatment of celiac disease today is to adhere to a life long gluten-
free diet (GFD). Strict compliance is essential for mucosal recovery and prevention of 
complications. Since gluten is a very common ingredient in our diet, this presents a 
big challenge for celiac disease patients and adherence to GFD is estimated to be only 
40-80% (Högberg et al., 2003; Leffler et al., 2007). Furthermore, the gluten-free 
products are often more expensive and many find the diet unpalatable. A large 
fraction of the celiac disease patients cannot adhere to this strict gluten-free diet. 
Especially those who are asymptomatic may find it hard. There are also some patients 
that do not respond to dietary therapy. They therefore have a strong desire for 
alternative therapies. If a treatment was available so that some gluten could be 
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ingested, their quality of life would improve. However, to be on a gluten-free diet is 
safe and effective and this must be taken into account for new therapies. 
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AIMS OF THE STUDY 
The focus of this thesis has been to characterize peptide binding to HLA-DQ2 in 
detail and to develop blocking agents for the treatment of celiac disease. 
 
The specific aims of the present studies were to: 
1. Investigate the relative contribution of each main chain amide hydrogen bond 
interaction between HLA-DQ2 and peptide. 
2. Examine the hydrogen bond between HLA-DQ2 and the P1 amide nitrogen in 
peptides without Pro at this position. 
3. Characterize HLA-DQ2.5 binding frames of DQ2 gluten T cell epitopes 
4. Investigate peptide binding of DQ2 gluten T cell epitopes to HLA-DQ2.2 
5. Design and synthesize cyclic peptides for the treatment of celiac disease 
6. Examine the blocking peptides for binding to HLA-DQ2 and inhibition of T 
cell recognition of antigen 
7. Investigate which HLA class II molecules the DQ2 gluten T cell epitopes 
recognized by T cells of celiac disease patients are able to bind to.  
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SUMMARY OF PAPERS 
Paper I 
Main chain hydrogen bond interactions in the binding of proline-rich gluten 
peptides to the celiac disease-associated HLA-DQ2 molecule 
Elin Bergseng, Jiang Xia, Chu-Young Kim, Chaitan Khosla, Ludvig M. Sollid 
 
This study demonstrates that there are hydrogen bonds important for binding of 
peptides to HLA-DQ2 at positions P2 and P4. There are also hydrogen bonds at P6 
and P9, but these are less important, and there is no evidence for a hydrogen bond in 
position P1. These observations explain the non-random positioning of Pro in gluten T 
cell epitopes when bound to the HLA-DQ2 molecule. They also explain why HLA-
DQ2 can accommodate Pro residues at position P1 with no penalty despite the lack of 
hydrogen bond to the peptide backbone. This is a unique feature of HLA-DQ2 and is 
likely a key parameter for preferential binding of Pro-rich peptides and the 
development of celiac disease. The information of the paper is also useful for the 
design of agents that block presentation of peptides by HLA-DQ2 which potentially 
can be used for the treatment of celiac disease. 
 
Paper II 
Refining the rules of gliadin T cell epitope binding to the disease-associated DQ2 
molecule in celiac disease: importance of proline spacing and glutamine 
deamidation  
Shuo-Wang Qiao, Elin Bergseng, Øyvind Molberg, Günther Jung, Burkhard 
Fleckenstein, Ludvig M. Sollid 
 
In this study two novel epitopes in -gliadin were characterized and fine mapping of 
the HLA-DQ2.5 binding frame of these and three previously reported epitopes were 
undertaken. Alignment of the gluten T cell epitopes revealed Pro residues in positions 
P1, P3, P5, P6 and P8, but never in positions P2, P4, P7 and P9. It was also shown 
that several Gln residues in these epitopes were targeted by TG2, but only Glu 
residues in positions P4, P6 and rarely P7 was important for T cell recognition. In 
addition, nine DQ2 gluten T cell epitopes were screened for binding to HLA-DQ2.2 
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and presentation by HLA-DQ2.2 APC. The majority of these epitopes were 
recognized by T cells and this ability was not related to the absence of Pro in the P3 
pocket as suggested earlier. However, the HLA-DQ2.5 presentation is more efficient 
than HLA-DQ2.2 presentation of the DQ2.5 gluten T cell epitopes and this could be 
the reason for the differential risk associated with these two molecules. 
 
Paper III 
Cyclic and dimeric gluten peptide analogues inhibiting DQ2-mediated antigen 
presentation in celiac disease 
Jiang Xia*, Elin Bergseng*, Burkhard Fleckenstein, Matthew Siegel, Chu-Young Kim, 
Chaitan Khosla, Ludvig M. Sollid 
*These authors contributed equally to the work. 
 
In this study cyclic and dimeric peptides were studied as blockers of HLA-DQ2 
-mediated antigen presentation in celiac disease. Our results demonstrate proof-of-
principle of these peptides for inhibition of HLA-DQ2-mediated presentation of 
gluten T cell epitopes. These blocking agents therefore represent a promising class of 
compounds for MHC blockers. The future challenge in relation to celiac disease will 
be to generate compounds that bind to DQ2 with higher affinities. 
 
Paper IV 
Binding of gluten T cell epitopes to various HLA class II molecules 
Elin Bergseng, John Sidney, Alessandro Sette, Ludvig M. Sollid 
 
In this study we aimed to shed light on peptide determinant selection by HLA-DQ2 as 
a factor to explain the strong HLA association in celiac disease. A panel of peptides 
representing DQ2 gluten T cell epitopes was tested for binding to various HLA class 
II molecules. Three different experimental approaches were used for assessing 
binding. The results demonstrated that the gluten T cell epitopes mainly bind to HLA-
DQ2 and not to other HLA class II molecules. This contributes to explaining the 
strong HLA association with HLA-DQ2 in celiac disease. 
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METHODOLOGICAL CONSIDERATIONS 
Peptide binding assays 
Competitive MHC class II peptide binding assay 
We have used a traditional competitive inhibition assay with detergent solubilized 
MHC class II molecules (Buus et al., 1986) or recombinant soluble HLA-DR3 
molecule (Quarsten et al., 2001; Fallang et al., 2007) in our studies to assess the 
binding efficiency of peptides. This is an indirect assay where the binding capacity of 
the peptide is measured as the ability to inhibit binding of a 125I-labeled indicator 
peptide. The high affinity indicator peptide was labeled by the chloramine T method 
(Greenwood and Hunter, 1963). The affinity purified MHC class II molecules were 
incubated with radiolabeled indicator peptide in the presence of increasing 
concentration of peptide to be tested, a mixture of protease inhibitors and a citrate-
phosphate pH buffer at 37°C as described by Johansen et al (Johansen et al., 1994). 
Complexes of peptide and MHC class II molecule were separated from free peptides 
by a spin column chromatography technique (Buus et al., 1995). The results are given 
as the IC50 value, which is the concentration of the peptide needed to inhibit 50% of 
the binding of the high affinity radiolabeled indicator peptide. The lower the IC50 
value, the better the peptide bind to the MHC class II molecule. In the experiments 
where recombinant soluble HLA-DR3 molecules were used, HLA-DM was added to 
increase the peptide exchange and thereby reducing the amount of MHC class II 
molecules needed for achieving 10-15% binding of the indicator peptide. Under 
equilibrium conditions where [labeled indicator peptide] < [MHC class II molecule] 
and IC50  [MHC class II molecule], the measured IC50 values are reasonable 
approximations of the KD values. Due to a sustained release of endogenously bound 
peptides from the naturally purified MHC class II molecules, complete equilibrium 
has likely not been reached in many of these assays, which is a weakness in the 
assessment of peptide binding. 
 
For comparison of peptides that have been tested on different days or with different 
preparations of affinity purified MHC class II molecules, relative binding values 
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appear to be more accurate and consistent than comparing the IC50 values, since IC50 
values varies between two experiments. 
 
Peptide binding in an antibody based catch assay with cell lysates 
Peptide binding was also assayed in an antibody based catch assay modified from 
Stepniak et al (Stepniak et al., 2005). This assay was used to test a panel of 
biotinylated gluten T cell epitopes for binding to various MHC class II molecules. 
MHC class II molecules in cell lysates of B-lymphoblastoid cell lines were caught 
either with a DQ-specific antibody (SPV-L3), a DR-specific antibody (L243) or a DP-
specific antibody (B7/21). Binding of biotinylated gluten peptides was measured by 
time-resolved fluorometry using europium-labeled streptavidin. This assay is less 
labor some and less accurate than the competitive MHC class II peptide binding assay 
described above. However, it has the ability to screen many different MHC class II 
molecules including those of the DRB3, DRB4 and DRB5 loci. The amount of MHC 
class II molecules in the different cell lines was not quantified. Comparison between 
cell lines and MHC class II molecules should therefore be done with caution. 
 
Competitive inhibition in an antibody based catch assay 
This assay is similar to the competitive MHC class II peptide binding assay described 
above. However, while the unbound peptides are separated from bound peptides by a 
spin column chromatography technique in the assay described above, MHC binding 
of the radiolabeled peptide was determined by capturing peptide-MHC complexes on 
LB3.1 (anti-HLA-DRA) antibody coated Lumitrac 600 plates and measuring bound 
cpm. 
 
Peptide exchange assay 
Recombinant soluble HLA-DQ2 molecules were treated with thrombin to release the 
covalently linked DQ2--I-gliadin peptide and incubated with fluorescein-conjugated 
peptide in a 25:1 ratio at 37°C in PBS with a citrate-phosphate buffer (pH 5.5 or pH 
7.3). Peptide binding was measured by high performance size exclusion 
chromatography (HPSEC). The fluorescence signal was recorded and the peak areas 
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corresponding to peptide-MHC complex and the free peptide were used to calculate 
the percentage of bound peptide. In this assay, directly labeled peptides are required. 
 
Dissociation experiments 
In the dissociation experiment, detergent solubilized HLA-DQ2 molecules were 
loaded with a radiolabeled peptide. These peptide-DQ2 complexes were isolated by 
the spin column chromatography technique (Buus et al., 1995) and then incubated at 
pH 5.2 at 37°C. Samples were taken at various time points and separated on the spin 
columns. The fraction of bound peptide was calculated. The experiments were 
performed without a competing unlabeled peptide. However, the effect of competing 
unlabeled peptide in excess was examined and the dissociation rates were found to be 
similar.  
 
T cell proliferation assay 
T cell proliferation as a result of T cell receptor recognition of antigen was assessed in 
a 3H-thymidine incorporation assay. Fixed or -irradiated HLA-DR3/DQ2 
homozygous Epstein Barr virus transformed B lymphoblastoid cell lines were used as 
APC. Antigen and APC were incubated overnight to allow for presentation of the 
peptide before T cells were added. In the T cell blocking experiments, the blocking 
peptide and antigen were incubated overnight with APC. These assays were 
commonly performed with fixed APC. However, we showed in paper III that a 
dimeric peptide (peptide 8) was blocking antigen presentation with irradiated APC. In 
the blocking experiments a T cell clone (TCC) with a specificity other than the one 
the peptide was based on were chosen to avoid the possibility of altered peptide ligand 
phenomena. For the cyclic peptides based on the DQ2--I-gliadin epitope in paper III, 
a DQ2--II specific TCC was chosen for testing. An experiment with an HLA-DR3 
restricted TCC specific for Mycobacterium tuberculosis 65-kDa Hsp 3-13 epitope was 
included to test for unspecific effects in the blocking assay. An HLA-DR3 restricted T 
cell clone was chosen since the APC express both HLA-DR3 and -DQ2. 
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Expression of recombinant soluble peptide-MHC class 
II molecules in a baculovirus expression system 
Recombinant soluble HLA-DQ2 and -DR3 molecules were expressed in the 
baculovirus expression system as previously described (Quarsten et al., 2001; Fallang 
et al., 2007). A complementary Fos/Jun leucine zipper dimerization motifs replaced 
the transmembrane region of the  and  chains and a peptide was covalently linked to 
the N-terminus of the  chain by a linker including a thrombin site. The molecules 
were expressed in expresSF+ serum free insect cells to avoid contamination of serum 
proteins. Prior to use in the peptide binding assays, the molecules were treated with 
thrombin. 
 
Peptide synthesis of cyclic peptides 
The linear peptides were synthesized by Fmoc/PyBOP chemistry on TentaGEL 
SRAM resin using an automated synthesizer. The N-termini were acetylated before 
the peptides were cyclized on the resin. The Lys residues were protected with 1-(4,4-
dimethyl-2,6-dioxycyclohex-1-ylidene)ethyl (Dde) groups, which was selectively 
removed with 1% hydrazine in DMF. The peptides were cyclized by coupling 
dicarboxy polyethylene glycol (PEG) between the two Lys residues. In peptide 4 
(terminology from paper III) bis-dPEG7-acid (HO2CCH2CH2(CH2CH2O)7CO2H) 
with a defined length was used to cyclize the peptide, while peptide 5 was cyclized by 
poly(ethyleneglycol)bis(carboxymethyl)ether (HO2CCH2(OCH2CH2)OCH2CO2H) 
with an average MW of 600. A mix of the dicarboxylic acid, PyBOP, 
diisopropylethylamine and the peptide on resin were incubated overnight. A 
completed reaction was verified by a negative ninhydrin test. Peptides were 
deprotected and cleaved from the resin with 95% TFA and 2.5% water and 2.5% 
triisopropylsilan as scavengers. Precipitation of peptides was carried out by the 
addition of icecold tert-butyl methyl ether and thereafter the peptides were dissolved 
in water and lyophilized. The peptides were analyzed by reverse phase HPLC and 
MALDI-TOF mass spectrometry. Peptides were dissolved, aliquoted and lyophilized 
before storage at -20°C. Notably, peptide 5 contains a mixture of peptides with 
various length of the PEG linker. 
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GENERAL DISCUSSION 
HLA association in celiac disease  
The HLA association in celiac disease can be explained by the ability of HLA-DQ2 to 
bind the Pro- and Gln-rich gluten peptides that have survived the gastrointestinal 
digestion and have been deamidated by TG2. It has been demonstrated that HLA-DQ2 
has a preference for binding peptides with amino acids with negative charges at the 
relative positions P4, P6 and P7 (Johansen et al., 1996; van de Wal et al., 1996), while 
HLA-DQ8 has a preference for binding peptides with negatively charged residues at 
relative positions P1 and P9 (Kwok et al., 1996; Godkin et al., 1997; Moustakas et al., 
2000; Lee et al., 2001; Suri et al., 2005; Tollefsen et al., 2006). Gluten proteins 
naturally have remarkably few negatively charged amino acids. The HLA-DQ2 
restricted presentation of gluten peptides was therefore a mystery until the observation 
of preferential recognition of deamidated gluten peptides by T cells of celiac lesions 
(Sjöström et al., 1998), and the discovery of TG2 being able to deamidate gluten 
peptides (Molberg et al., 1998; van de Wal et al., 1998a). In the x-ray crystal structure 
of HLA-DQ2 complexed with the DQ2--I-gliadin peptide, it was shown that the Glu 
in P6 participates in a hydrogen bonding network involving Lys-71 of HLA-DQ2 
(Kim et al., 2004). The Lys-71 is positioned so that it can also interact with 
negatively charged residues in the P4 or P7 positions. 
 
A network of hydrogen bonds between conserved MHC residues and the peptide main 
chain carbonyl oxygen and amide nitrogen groups contributes to much of the energy 
for binding of peptides to MHC class II molecules. Amide nitrogen hydrogen bonds 
are commonly in positions P1, P2, P4, P6 and P9 (reviewed in Nelson and Fremont, 
1999). In paper I we demonstrated that the hydrogen bonds in position P2 and P4 are 
most important for binding in HLA-DQ2, while the hydrogen bonds in P6 and P9 
made smaller contributions. Pro residues in the peptide are not able to engage in 
amide hydrogen bonding. As the DQ2--I-gliadin peptide has a Pro residue in P1, a 
hydrogen bond is therefore not seen in this position in the x-ray crystal structure. The 
Pro cannot act as a hydrogen bond donor in the peptide due to its tertiary nitrogen. 
However, we did not find any evidence of a hydrogen bond in this position when 
testing peptides without Pro at this position. This may explain why DQ2 can 
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accommodate Pro residues in this position without any penalty. As discussed in paper 
I, the reason for this could be the deletion of residue 53 in the  chain of HLA-DQ2. 
To further investigate this, a recombinant soluble HLA-DQ2 molecule with either Arg 
or Gly inserted in this position was constructed and expressed (Bergseng et al, 
unpublished). This may restore the hydrogen bond and a longer dissociation of the 
peptide is therefore expected. Unfortunately, the dissociation of the peptides tested 
was very fast. The insertion of an amino acid may possibly change the three 
dimensional structure of the molecule, thereby disrupting the binding groove. The 
positioning of Pro residues in the gluten peptides is important to avoid loss of any of 
the hydrogen bonds. In paper II it was demonstrated that Pro residues are found at 
positions P1, P3, P5, P6 and P8 and never at positions P2, P4, P7 and P9. This non 
random positioning of Pro residues explains the ability of DQ2 to accommodate the 
Pro-rich gluten peptides without any loss of binding energy with negatively charged 
anchor residues at P4, P6 or P7. 
 
Alternative treatments for celiac disease 
Detailed knowledge of the molecular mechanisms of celiac disease should allow us to 
rationally design new therapeutic agents to treat the disease. As HLA-DQ2 and -DQ8 
are common among the general population and almost all celiac disease patients 
express HLA-DQ2 or -DQ8, these molecules are necessary but not sufficient for the 
development of celiac disease. This indicates that activation of gluten specific CD4+ T 
cells by presentation of gluten peptides in context of HLA-DQ2 or -DQ8 is one of the 
key features in celiac disease development. Interference with activation of gluten 
specific T cells should therefore control the disease, and one can envisage several 
possible avenues to accomplish this (Green and Jabri, 2003; Sollid and Khosla, 2005).  
 
To be acceptable, the therapies for celiac disease have to be safe, effective and 
affordable since a dietary alternative is already available. Potential treatment 
strategies can be divided into two classes, modifying gluten or modifying the immune 
response to gluten. To grow genetically modified wheat lacking the gluten T cell 
epitopes is one alternative. Another strategy is to breed wheat cultivars with low or 
absent levels of harmful gluten proteins with the baking quality of wheat species 
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commonly used today (Frisoni et al., 1995; Molberg et al., 2005; Spaenij-Dekking et 
al., 2005a; Spaenij-Dekking et al., 2005b). The gluten reactive T cells from intestinal 
biopsies can recognize a broad repertoire of gluten peptides and these differs from 
patient to patient. Wheat has complex genetics and all epitopes are not known. It will 
be difficult to delete all the genes encoding T cell stimulatory epitopes and still retain 
the baking quality. Genetic modifications also raise concerns about safety and ethics. 
The search for naturally occurring wheat variants with fewer T cell epitopes than 
common bread wheat used today could be a better starting material for detoxification. 
 
Enzyme supplementation that can cleave the gluten peptides into short inactive 
sequences is also an approach for detoxification of gluten. Several endopeptidases 
have been described. A prolyl endopeptidase (PEP) that cleaves Pro-rich peptides was 
the first to be described (Shan et al., 2002; Hausch et al., 2002; Piper et al., 2004; 
Marti et al., 2005; Matysiak-Budnik et al., 2005). This enzyme is going to be tested in 
clinical trials in combination with a cysteine endoprotease (EP-B2) (Siegel et al., 
2006; Gass et al., 2007). Another prolyl endopeptidase which has been described to be 
efficient is AN-PEP from Aspergillus niger (Stepniak et al., 2006). However, enzyme 
therapy has some disadvantages as well. The gluten in normal food may not be easily 
accessible and thus hard to degrade, so the efficiency of the oral proteases is 
questionable.  
 
There are also several possibilities to modify the immune response to gluten. Blocking 
the binding site of HLA-DQ2 and -DQ8 will prevent the presentation of gluten 
peptides and thereby also T cell activation (Xia et al., 2006; Siegel et al., 2007; 
Kapoerchan et al., 2007). Peptide blockers will possibly have few side effects since 
many healthy individuals are homozygous for HLA alleles. Thus, immunosuppression 
or infections are unlikely. Inhibition of TG2 will prevent the production of 
deamidated immunogenic epitopes (Siegel et al., 2007; Siegel and Khosla, 2007). 
Inhibitors of TG2 may create unpredicted adverse effects since TG2 has a diverse 
biological role. However, TG2 knockout mice appeared to have a normal phenotype 
(De Laurenzi and Melino, 2001; Nanda et al., 2001). In addition, the efficiency is 
questionable since there are gluten T cell epitopes which seems not to be dependent 
on deamidation (Vader et al., 2002b; Dewar et al., 2006). Silencing of the gluten 
reactive T cells by soluble HLA-peptide complexes is another alternative, but this is 
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complicated by the broad repertoire of gluten T cell epitopes. It has also been 
suggested to induce tolerance by intranasal administration of gluten (Maurano et al., 
2001; Senger et al., 2003). Cytokine therapy targeting IL-15, IL-10 and IFN- is also 
a possibility. IL-15 and IFN- play important roles in the celiac disease pathogenesis 
and their neutralization may have a therapeutic effect (Nilsen et al., 1995; Mention et 
al., 2003). Also, recombinant IL-10 may possibly down regulate the Th1 response 
dominating in celiac disease (Mulder et al., 2001; Salvati et al., 2005). Other possible 
targets are chemokines and adhesion molecules. These molecules assist in the 
recruitment of inflammatory cells to inflamed sites. Blockade of these molecules may 
therefore be an approach to reduce the number of inflammatory cells. However, an 
increased susceptibility to infections may be a potential side effect of this therapy. 
Other options may be to use NK receptor antagonists or zonulin antagonists (Fasano 
et al., 2000; Hüe et al., 2004; Meresse et al., 2004; Drago et al., 2006).  
 
In paper III we studied cyclic and dimeric peptides as peptide blockers of HLA-DQ2. 
Blocking of peptide presentation by HLA molecules has been a suggested therapy for 
other HLA associated diseases (Sette et al., 1991). It is well documented that peptide 
blockers can effectively interfere with T cell activation both in vitro and in vivo 
(Adorini et al., 1988; Sakai et al., 1989; Hurtenbach et al., 1993). Interference of HLA 
class II restricted antigen presentation by altered peptide ligands (antagonists) has also 
been explored (Sloan-Lancaster and Allen, 1996; de Haan et al., 2005), but this 
approach would not be feasible for celiac disease due to the many gluten-derived T 
cell epitopes and the polyclonal nature of T cells recognizing the same epitope. This 
therapeutic concept of inhibiting antigen presentation to T cell was not developed 
further mainly because the delivery of the peptide based drug into the affected organs, 
like joints of rheumatoid arthritis and  cells in the pancreas in type 1 diabetes, proved 
difficult (Ishioka et al., 1994). However, the situation in celiac disease is different. 
The peptide blockers will be delivered onto the intestinal mucosa in parallel with the 
gluten peptides to out-compete. This is much easier compared with delivery to antigen 
presenting cells of the joints in rheumatoid arthritis or the islet  cells of the pancreas 
in type 1 diabetes.  
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Peptide based compounds as drugs 
Peptides offer several advantages over small molecules (increased specificity and 
lower toxicity) and antibodies (better tissue penetration due to smaller size) as 
potential therapeutics. Nevertheless a number of key issues have hampered their use. 
In most cases peptides have poor in vivo stability, poor pharmacokinetics and poor 
bioavailability (Soares et al., 2007). Thus, most peptides cannot be administered 
orally as they are rapidly inactivated by gastrointestinal enzymes and poorly absorbed. 
Solubility may also be a problem depending on the amino acid sequence. In addition 
they are expensive to produce. 
 
As gluten is ingested, it is subject to extensive proteolysis in the gastrointestinal tract 
by gastric, pancreatic and intestinal brush border membrane enzymes. It has, however, 
been shown that the gluten T cell epitopes are extremely stable against proteolysis 
(Hausch et al., 2002; Shan et al., 2002; Shan et al., 2005). The identification of a 33-
mer peptide containing multiple copies of known T cell epitopes DQ2--I, DQ2--II 
and DQ2--III, were shown to survive extensive proteolysis (Shan et al., 2002). To 
overcome the problem of proteolytical instability, we have used a gliadin peptide as a 
starting point for our peptide blockers. 
 
Gluten peptides must cross the intestinal epithelial barrier and reach the lamina 
propria where they are presented by antigen presenting cells to CD4+ T cells. How 
this happen is still unclear. The intestinal epithelial barrier is normally almost 
impermeable to macromolecules. However, it has been demonstrated that untreated 
celiac disease patients have increased intestinal permeability (Hamilton et al., 1982) 
with a compromised tight junction system (Madara and Trier, 1980; van Elburg et al., 
1993; Schulzke et al., 1998). It has been suggested that up-regulation of zonulin, a 
molecule claimed to affect tight junction function, could at least partly be responsible 
for the increased gut permeability (Fasano et al., 2000; Wang et al., 2000). Gliadin 
peptides are also shown to be taken up by enterocytes by endocytosis (Friis et al., 
1992). Zimmer et al has demonstrated that the gliadins are translocated to late 
endosomes or lysosomes in untreated celiac disease patients (Zimmer et al., 1995). 
Later they showed that gliadin peptides were located in vacuoles and Golgi complexes 
in enterocytes of celiac disease patients with active disease (Zimmer et al., 1998). 
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Another alternative by which gluten peptides could be taken up is through direct 
sampling from the lumen by dendritic cells which is shown in mice (Rescigno et al., 
2001; Niess et al., 2005). M cells and defects in the intestinal transport are also 
possible routes through which gliadin could be taken up. The uptake of the peptide 
blocker will probably use the same entrance as the gluten peptides. 
 
Peptide blockers 
A peptide blocker should not serve as a TCR ligand for any T cell as it then could 
elicit hypersensitivity reactions. Conceptually there are two ways this can be 
achieved. The peptide can be big and bulky thereby avoiding the docking of any TCR 
onto the peptide-MHC complex. Alternatively, the peptide can be small and invisible 
thereby allowing the TCR to dock onto the peptide-MHC complex, but avoiding TCR 
recognition (Figure 4).  
 
 
 
Figure 4. Schematic representation of peptide and peptide blockers in the peptide 
binding groove of the HLA class II molecule. 
 
In paper III, two types of sterically hindered peptides were studied as peptide 
blockers; cyclic and dimeric peptides. The concept of cyclic peptides as peptide 
blockers is not new. It has been described by Bouvier et al for MHC class I molecules 
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(Bouvier and Wiley, 1996). It is unlikely that any TCR could dock onto a cyclic 
peptide when bound to an MHC molecule, and thus there should not be a problem of 
hypersensitivity reactions to cyclic blockers. Another advantage is that cyclic peptides 
are more proteolytically stable than the linear peptide (Matsoukas et al., 2005). 
 
In paper III we demonstrated that our peptide blockers bind to HLA-DQ2, they inhibit 
T cell proliferation and they are specific for HLA-DQ2. However, the peptide 
blockers appear not to have sufficient efficiency to be used as therapeutic agents. This 
may be achieved by increasing binding affinity for HLA-DQ2. A peptide blocker 
needs to be potent since several studies have demonstrated that very few peptide-
MHC complexes (1-400) can trigger antigen-specific T cells (Demotz et al., 1990; 
Harding and Unanue, 1990; Kimachi et al., 1997; Reay et al., 2000; Irvine et al., 
2002).  
 
Final comments  
The use of peptide blockers as therapeutic compounds is favorable due to their easy 
access to the small intestine. However, the poor pharmacokinetic properties like 
stability and bioavailability of peptides as drugs has to be overcome. Thus a peptide 
blocker should bind with high affinity to DQ2, be stable against proteolysis and not be 
recognized by any T cell. To use a gluten peptide as starting point for a peptide 
blocker could solve the problem with proteolytic instability of peptides. The 
possibility of a hypersensitivity reaction to occur is reduced by using cyclic peptides 
as peptide blockers. The major problem is to increase the binding affinity of the 
peptide blocker. An effective peptide blocker should most likely have an affinity 
which is at least 100-fold higher than the gluten peptides. Several groups are working 
on how to increase the binding affinity. If such a high affinity and proteolytically 
resistant peptide is found, the concept of peptide blockers could be ready for testing in 
clinical trials. 
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ERRATA 
Paper I: 
Page 21792, right column, line 14 in Results 
The correct should be: 
(23.3- and 35.6-fold, respectively) 
 
Paper IV: 
Page 1 
The title should be: 
 Analysis of the binding of gluten T-cell epitopes to various human leukocyte antigen 
class II molecules 
 
Page 6 line 10 
The correct should be:  
The antibodies used in this study are L243 (anti-DR) [13], B8.11 (anti-DR) [14], 
LB3.1 (anti-DRA) [15], SPV-L3 (anti-DQ) [16], 2.12.E11 (anti-DQ2) [17] and B7/21 
(anti-DP) [18]. 
 
Page 6 line 19 
The correct should be: 
Detergent solubilized DQ2.5 (DQA1*0501, DQB1*0201) and DR3 (DRA*0101, 
DRB1*0301) molecules were purified from the Epstein-Barr virus-transformed B-
LCL, 9023 VAVY and CD114, as described previously [19] using specific mAbs, 
2.12.E11 and B8.11, respectively. 
 
 

